Title: Efficacy and safety of one-puff, once-daily, evening treatment with mometasone furoate dry-powder inhaler 400 mcg compared with fluticasone propionate metered dose inhaler 125 mcg two puffs, twice daily in asthma patients switched from fluticasone propionate
Abstract: RATIONALE: Previous studies have shown that TAA AQ and FP are equally effective in the treatment of seasonal allergic rhinitis (SAR) symptoms.This conclusion was examined by stratifying patients of a previously reported trial by baseline disease severity.METHODS: In a multicenter, parallel group study, patients with >-2 year history of SAR (n=295) were randomized to TAA AQ (220 lag QD) or FP (200 lag QD) nasal spray for 3 weeks.Median baseline total symptom score (TSS) was 8.14 overall.Subjects were subsequently classified as moderate or severe depending on their baseline mean TSS (<8.0 vs >8.0, respectively).RESULTS: Sixty-nine TAA AQ and 76 FP patients were stratified into the moderate category (baseline mean TSS = 6.14 and 6.22, respectively), compared with 79 TAA AQ and 71 FP patients in the severe category (baseline mean TSS = 10.03 and 9.47, respectively).At the end of study, patients in the moderate category showed mean changes in TSS from baseline of -2.85 (-44%) with TAA AQ and -2.93 (-46.5%) with FP while patients in the severe category had mean changes of -4.84 (-47.7%) with TAA AQ and -4.81 (-47%) with FP.There was no statistically significant between-treatment difference for either population.ANCOVA analysis showed the mean difference in TSS between treatments at studyend was -0.02 (95% C! [~).54, 0.89]) in the moderate group and 0.31 (95% CI [-0.58, 1.21]) in the more severe group, CONCLUSIONS: Triamcinolone acetonide and fluticasone propionate demonstrated clinical equivalence for the relief of SAR symptoms regardless of disease severity.
Publication Year: 2003
Publication Date: 2003-02-01
Language: en
Type: article
Indexed In: ['crossref']
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot